Related Experiment Video
Updated: Feb 23, 2026
Rat Mesentery Angiogenesis Assay
Published on: June 18, 2011
Inhibitory effect of tenomodulin versus ranibizumab on in vitro angiogenesis
Wei Wang1, Guang-Xu Liu2, Yue-Hua Li1
1Department of Ophthalmology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China.
Aim:
To evaluate anti-angiogenic effect of tenomodulin (TNMD) and ranibizumab on cell proliferation and capillary-like morphogenesis of vascular endothelial cells under the stimulation of vascular endothelial growth factor (VEGF) in vitro.
Methods:
The effects of TNMD and ranibizumab on VEGF-induced proliferation of human umbilical vein endothelial cells (HUVECs) were evaluated by MTT assay, and the effects of TNMD and ranibizumab on capillary-like structures formed by HUVECs under the stimulation of VEGF were examined in culture. Capillary-like morphogenesis of HUVECs was quantitatively evaluated, and total lengths of tube-like structures per field were measured in a masked way.
Results:
HUVECs with both ranibizumab and TNMD protein showed MTT reduction in VEGF-stimulated cell proliferation as expected, while MTT absorbance in the HUVECs with TNMD was significantly declined than that with ranibizumab (P<0.01). The capillary-like structures formed by HUVECs were markedly impaired by the presence of both TNMD and ranibizumab in the culture medium. The total length of the capillary-like structures per field was significantly shorter in the medium with TNMD than that of ranibizumab (P<0.01). The inhibitory effect of TNMD on tube formation in vitro angiogenesis was significantly stronger than that of ranibizumab.
Conclusion:
TNMD may have stronger inhibitory effect than ranibizumab on in vitro angiogenesis.
Insights
Tenomodulin (TNMD) demonstrated a stronger inhibitory effect on in vitro angiogenesis than ranibizumab. Both TNMD and ranibizumab reduced vascular endothelial cell proliferation and capillary-like structure formation stimulated by vascular endothelial growth factor (VEGF).
Area of Science:
- * Ophthalmology and Angiogenesis Research
- * Molecular Biology and Cell Signaling
- * Biochemistry and Drug Discovery
Background:
- * Angiogenesis, the formation of new blood vessels, is crucial for physiological processes but also implicated in pathological conditions like wet age-related macular degeneration.
- * Vascular endothelial growth factor (VEGF) is a key regulator of angiogenesis.
- * Ranibizumab is an anti-VEGF antibody fragment used clinically to inhibit angiogenesis.
Purpose of the Study:
- * To compare the anti-angiogenic effects of tenomodulin (TNMD) and ranibizumab.
- * To evaluate their impact on vascular endothelial cell proliferation and capillary-like structure formation in vitro.
- * To assess their efficacy in inhibiting vascular endothelial growth factor (VEGF)-stimulated angiogenesis.
Main Methods:
- * In vitro study using human umbilical vein endothelial cells (HUVECs).
- * MTT assay to measure cell proliferation.
- * Assessment of capillary-like morphogenesis and quantitative measurement of tube formation.
Main Results:
- * Both TNMD and ranibizumab inhibited VEGF-induced HUVEC proliferation.
- * TNMD showed a significantly greater reduction in cell proliferation compared to ranibizumab (P<0.01).
- * Both agents impaired capillary-like structure formation, with TNMD exhibiting a significantly stronger inhibitory effect than ranibizumab (P<0.01).
Conclusions:
- * Tenomodulin (TNMD) exhibits a more potent inhibitory effect on in vitro angiogenesis than ranibizumab.
- * TNMD significantly suppresses both endothelial cell proliferation and tube formation.
- * TNMD represents a potential therapeutic agent for angiogenesis-related diseases.
Related Concept Videos
01:10Mechanism of Angiogenesis
01:24Regulation of Angiogenesis and Blood Supply